The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led non-profit organization, comprised of 99% volunteers and represents 32,000 Waldenstrom’s patients worldwide! They want you to know with the IWMF, you are never alone and anyone can become a member. As the IWMF strives to support the lives of those living with this rare cancer, the organization offers critical services to achieve that end.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Waldenstrom Macroglobulinemia
Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?
On October 14th, 2020, the International Waldenström’s Macroglobulinemia Foundation (IWMF) hosted a webinar featuring Dr. Irene Ghobrial of the Dana Farber Cancer Institute. The focus
September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of
IWMF Webinar Provides In-Depth Info on WM
In a recent webinar hosted by the International Waldenström’s Macroglobulinemia Foundation (IWMF) and held on July 22nd, 2020, Dr. Jeffery Matous from the Colorado Blood
Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US
Study Aims to Discover How COVID-19 is Affecting WM Patients
A new study is seeking to understand how the ongoing coronavirus/COVID-19 pandemic is impacting patients with a rare blood cancer called Waldenström’s macroglobulinemia (WM). The
Zanubrutinib Versus Ibrutinib: Which is Better for WM?
According to a story from crweworld.com, the biopharmaceutical company BeiGene, Ltd. recently released the results of a phase 3 clinical trial. The goal of this
